NCT00268229View on ClinicalTrials.gov

Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Leukemia
Interventions
DRUG

cytarabine

300 mg/m2/day

DRUG

daunorubicin hydrochloride

45 mg/m2/day

DRUG

imatinib mesylate

dose escalation (300 mg/day to 800 mg/day).

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

The Cleveland Clinic

OTHER

NCT00268229 - Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter